O
Oncozenge AB
F:8LY
Oncozenge AB
F:8LY
Price:
0.661
EUR
3.93%
Market Closed
Market Cap:
€7.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Oncozenge AB
F:8LY
|
SE |
Balance Sheet
Balance Sheet Decomposition
Oncozenge AB
Oncozenge AB
Balance Sheet Decomposition is not available for
Oncozenge AB
Oncozenge AB
Balance Sheet
Oncozenge AB
Oncozenge AB
Currency: SEK
| Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
10
|
51
|
29
|
13
|
4
|
4
|
|
| Cash Equivalents |
10
|
51
|
29
|
13
|
4
|
4
|
|
| Total Receivables |
6
|
1
|
0
|
0
|
1
|
3
|
|
| Other Current Assets |
0
|
0
|
1
|
1
|
0
|
2
|
|
| Total Current Assets |
16
|
52
|
30
|
13
|
5
|
8
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
22
|
30
|
7
|
7
|
7
|
7
|
|
| Other Long-Term Assets |
1
|
3
|
0
|
0
|
0
|
9
|
|
| Total Assets |
38
N/A
|
85
+123%
|
37
-57%
|
20
-45%
|
11
-44%
|
24
+113%
|
|
| Liabilities | |||||||
| Accounts Payable |
0
|
0
|
2
|
1
|
1
|
7
|
|
| Accrued Liabilities |
3
|
0
|
1
|
1
|
1
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
6
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
5
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
9
|
5
|
3
|
2
|
1
|
8
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
8
|
|
| Total Liabilities |
9
N/A
|
5
-46%
|
3
-40%
|
2
-42%
|
1
-13%
|
16
+973%
|
|
| Equity | |||||||
| Common Stock |
1
|
0
|
1
|
1
|
1
|
1
|
|
| Retained Earnings |
16
|
0
|
5
|
51
|
67
|
76
|
|
| Additional Paid In Capital |
45
|
0
|
84
|
84
|
84
|
99
|
|
| Other Equity |
0
|
80
|
47
|
16
|
9
|
16
|
|
| Total Equity |
29
N/A
|
80
+174%
|
34
-58%
|
19
-45%
|
10
-47%
|
8
-15%
|
|
| Total Liabilities & Equity |
38
N/A
|
85
+123%
|
37
-57%
|
20
-45%
|
11
-44%
|
24
+113%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
9
|
12
|
12
|
12
|
12
|
13
|
|
Switch to:
Switch to:
Continue 8LY Research
Other Oncozenge AB listings:
Discover More
